Stock-Based Compensation

6 Months Ended

Jun. 30, 2020

Share-based Payment Arrangement [Abstract]

Stock-Based Compensation

Stock-Based Compensation

The table below summarizes the impact of recording stock-based compensation expense in the Condensed Consolidated Statements of Operations and Comprehensive Loss during the six months ended June 30, 2020 and 2019:

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Cost of goods sold	$	158	$	179	$	322	$	406
Operating expenses:
Research and development	176		331		357		663
Clinical and regulatory affairs	162		187		329		373
Marketing and sales	117		685		416		1,394
General and administrative	309		1,141		1,232		2,048
Total operating expenses	764		2,344		2,334		4,478
Total	$	922	$	2,523	$	2,656	$	4,884